Pharsight

1. List of Exondys 51 drug patents

Application	Filing Date	Opposition Party	Legal Status
EP17171389A	2023-01-09	Maiwald GmbH	Granted and Under Opposition
EP17171389A	2023-01-09	Bosch Jehle Patentanwaltsgesellschaft mbH	Granted and Under Opposition
EP13160338A	2016-10-06	Withers & Rogers LLP/Wright Howard/Wallin Nicholas	Revoked
EP08842559A	2016-09-22	Withers & Rogers LLP	Revoked
EP10004274A	2016-08-25	Nippon Shinyaku Co., Ltd.	Revoked
EP09788160A	2015-09-24	Howard Wright/ Nicholas Wallin/ Withers & Rogers LLP	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10781451	SAREPTA THERAPS INC	Antisense oligonucleotides for inducing exon skipping and methods of use thereof	Jun, 2025 (2 years from now)
US9018368	SAREPTA THERAPS INC	Antisense oligonucleotides for inducing exon skipping and methods of use thereof	Jun, 2025 (2 years from now)
US9243245	SAREPTA THERAPS INC	Means and methods for counteracting muscle disorders	Oct, 2028 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47751	SAREPTA THERAPS INC	Antisense oligonucleotides for inducing exon skipping and methods of use thereof	Jun, 2025 (2 years from now)
USRE48468	SAREPTA THERAPS INC	Means and methods for counteracting muscle disorders	Oct, 2028 (5 years from now)
USRE47769	SAREPTA THERAPS INC	Antisense oligonucleotides for inducing exon skipping and methods of use thereof	Feb, 2029 (5 years from now)
US10337003	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (10 years from now)
US10364431	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (10 years from now)
US9506058	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (10 years from now)

Do you want to check out EXONDYS 51 patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 19, 2023

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients having a mutatio...

Dosage: SOLUTION;INTRAVENOUS